Are you up-to-date on type 2 diabetes therapies?

While the number of agents for treating type 2 diabetes mellitus continues to increase, prescribers and clinicians may struggle with the need to individualize care as a means to improve treatment outcomes. » More

A prescription for specialty pharmaceuticals: Transparency and collaboration for improving drug and diagnosis coding on medical claims

By building collaborative strategies and using technology to assess protocols and communicate best practices, payers, clinicians, and pharmacies are now positioned to keep pace with new drugs and make the best decisions for patients—based both on clinical outcomes and cost. » More

Off-label use of atypical antipsychotics: Lack of evidence for their use in primary insomnia

For pharmacologic management of primary insomnia in the absence of other psychiatric or neurologic conditions for which atypical agents are helpful, other hypnotic agents should be tried. More research is required before expanding the prescribing of antipsychotics for insomnia. » More

Sales of leukemia chemotherapy drug suspended

Citing the risk of life-threatening blood clots and severe narrowing of blood vessels, FDA has asked Ariad Pharmaceuticals to suspend marketing and sales of ponatinib (Iclusig). » More

Study highlights need to address anaphylaxis prevention

Severe life-threatening allergic reactions are more common than many thought. Anaphylaxis very likely occurs in nearly 1 in 50 Americans (1.6%), and the rate is probably higher, close to 1 in 20 (5.1%), according to a study published in the Journal of Allergy and Clinical Immunology. » More

Downloads

You are subscribed to the Formulary Issue Alert.

BLOG: Optimize antibiotic stewardship

Pipeline preview

FDA actions in brief

New molecular entity